Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bahram Ahmadi

Gastroenterology Sebring, FL Medical Doctor

NPI 1003849001 CMS profile 45448

7441 US Highway 27 N, Sebring, FL 33870

Open in the dashboard

General payments

$14,485

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$66,081 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Bahram Ahmadi of Sebring, FL is reported in the CMS Open Payments database as having received $14,485 across 577 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $66,081 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $935 23
2024 General $1,925 61
2023 General $3,706 93
2022 General $2,230 110
2021 General $2,030 115
2020 General $1,178 65
2019 General $2,482 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bahram Ahmadi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Bahram Ahmadi were reported at $935. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Bahram Ahmadi Gastroenterology median Middle half National median
2019 $2,482 $417 $126–$1,100 $163
2020 $1,178 $224 $74–$624 $114
2021 $2,030 $352 $106–$1,054 $132
2022 $2,230 $448 $129–$1,270 $149
2023 $3,706 $533 $150–$1,390 $160
2024 $1,925 $605 $160–$1,606 $164
2025 $935 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,554 225 payments
  2. Arena Pharmaceuticals, Inc. $2,000 1 payment
  3. Gilead Sciences, Inc. $1,076 77 payments
  4. Pfizer Inc. $788 34 payments
  5. Olympus Corporation of the Americas $661 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $605 24 payments
  7. Nestle HealthCare Nutrition Inc. $473 28 payments
  8. Janssen Biotech, Inc. $386 18 payments
  9. Innovative Health Solutions, Inc. $374 2 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $346 24 payments
  11. Other $3,222 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,601 566 payments
  2. Consulting Fee $2,000 1 payment
  3. Travel and Lodging $661 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  5. Education $73 6 payments
Products named General payments · program years 2019–2025
  1. VELSIPITY $2,033 5 payments
  2. CREON $1,625 86 payments
  3. HUMIRA $879 45 payments
  4. LINZESS $873 41 payments
  5. RINVOQ $800 42 payments
  6. MAVYRET $698 32 payments
  7. XELJANZ $676 32 payments
  8. Olympus $661 3 payments
  9. DISPOSABLE DISTAL ATTACHMENT $661 3 payments
  10. STELARA $483 19 payments
  11. Other $5,911 282 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,556

Median for Gastroenterology: 569

Drug cost

$341,091

Median for Gastroenterology: $104,976

Branded share of claims

24.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 40 $136,139
Creon Lipase/Protease/Amylase Brand 31 $102,568
Linzess Linaclotide Brand 68 $70,396
Sucralfate Generic 165 $5,156
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 28 $4,703
Famotidine Generic 363 $3,789
Pantoprazole Sodium Generic 321 $3,521
Omeprazole Generic 243 $3,010
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 46 $2,720
Colestipol Hcl Generic 22 $2,095

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$136,272

Medicare's payments for the services billed

Medicare patients

707

Average age 73

Services billed

1,502

401 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 39%
Chronic kidney disease 36%
Diabetes 34%
Depression 34%
COPD 28%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $131
$131 — —
CREON
  • AbbVie, Inc. $96
$96 31 —
SKYRIZI
  • AbbVie, Inc. $69
$69 — —
LINZESS
  • AbbVie, Inc. $54
$54 68 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record